ED-71 Ameliorates Bone Loss in Type 2 Diabetes Mellitus by Enhancing Osteogenesis Through Upregulation of the Circadian Rhythm Coregulator BMAL1
Ting Liu,Luxu Wang,Tuo Shi,Hongrui Liu,Bo Liu,Jie Guo,Minqi Li
DOI: https://doi.org/10.2147/dddt.s470684
IF: 4.3188
2024-09-01
Drug Design Development and Therapy
Abstract:Ting Liu, 1, 2 Luxu Wang, 1– 3 Tuo Shi, 4 Hongrui Liu, 1, 2 Bo Liu, 5 Jie Guo, 1, 2 Minqi Li 1, 2, 5 1 Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, People's Republic of China; 2 Center of Osteoporosis and Bone Mineral Research, Shandong University, Jinan, People's Republic of China; 3 School of Stomatology, Jinzhou Medical University, Jinzhou, People's Republic of China; 4 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 5 School of Clinical Medicine, Jining Medical University, Jining, People's Republic of China Correspondence: Bo Liu, School of Clinical Medicine, Jining Medical University, Jining, 272067, People's Republic of China, Tel +86-0537-6051782, Email Jie Guo, Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, Shandong, 250012, People's Republic of China, Tel +86-0531-88382923, Email Purpose: Bone loss is a common complication of type 2 diabetes mellitus (T2DM). Circadian rhythms play a significant role in T2DM and bone remodeling. Eldecalcitol (ED-71), a novel active vitamin D analog, has shown promise in ameliorating T2DM. We aimed to investigate whether the circadian rhythm coregulator BMAL1 mediates the anti-osteoporotic effect of ED-71 in T2DM and its associated mechanisms. Methods: A T2DM mouse model was established using high-fat diet (HDF) and streptozotocin (STZ) injection, and blood glucose levels were monitored weekly. HE staining, Masson staining, and Micro-CT were performed to assess the changes in bone mass. IHC staining and IF staining were used to detect osteoblast status and BMAL1 expression and RT-qPCR was applied to detect the change of oxidative stress factors. In vitro, high glucose (HG) stimulation was used to simulate the cell environment in T2DM. RT-qPCR, Western blot, IF, ALP staining and AR staining were used to detect osteogenic differentiation and SIRT1/GSK3β signaling pathway. DCFH-DA staining was used to detect reactive oxygen species (ROS) levels. Results: ED-71 increased bone mass and promoted osteogenesis in T2DM mice. Moreover, ED-71 inhibited oxidative stress and promoted BMAL1 expression in osteoblasts The addition of STL1267, an agonist of the BMAL1 transcriptional repressor protein REV-ERB, reversed the inhibitory effect of ED-71 on oxidative stress and the promotional effect on osteogenic differentiation. In addition, ED-71 facilitated SIRT1 expression and reduced GSK3β activity. The inhibition of SIRT1 with EX527 partially attenuated ED-71's effects, whereas the GSK3β inhibitor LiCl further enhanced ED-71's positive effects on BMAL1 expression. Conclusion: ED-71 ameliorates bone loss in T2DM by upregulating the circadian rhythm coregulator BMAL1 and promoting osteogenesis through inhibition of oxidative stress. The SIRT1/GSK3β signaling pathway is involved in the regulation of BMAL1. Keywords: eldecalcitol, type 2 diabetic mellitus, osteoblast, BMAL1, SIRT1/GSK3β signaling pathway Diabetes mellitus (DM), the third most prevalent chronic metabolic disease, has emerged as a significant worldwide public health concern in the modern world. 1 Type 2 diabetes mellitus (T2DM) constitutes the predominant form, accounting for more than 90% of DM cases, and is associated with complications affecting various organs and tissues, including cardiovascular disease, osteoporosis, and neuropathy. 2,3 The association between T2DM and bone loss has recently garnered increased attention. The concept of type 2 diabetic osteoporosis (T2DOP) has been proposed, characterized by low bone mass and deterioration of bone microstructure, leading to fragile bones prone to fractures. 4 A recent cohort study revealed prevalence rates of bone loss and osteoporosis in patients with T2DM at 50.6% and 17.7%, respectively. 5 Although patients with T2DM sometimes show an increase in bone mineral density (BMD), the incidence of fractures is significantly increased. A number of studies have noted reduced bone turnover in patients with T2DM, which with decreas -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal